Medtronic plc (MDT) Revenue by Segment

Medtronic revenue by segment at a glance

In Q1 fiscal 2027 (the quarter ended July 31, 2026), Medtronic's largest business segment was Cardiovascular, with $3.93 billion or 40% of revenue, up 19.5% from a year earlier. Next: Neuroscience Group (27%), Medical Surgical (23%) and Diabetes Group (9%).

By region, United States brought in 50% and Non-US brought in 50% of revenue in Q1 fiscal 2027.

By country, United States brought in 50%, Total Other Countries, Excluding United States and Ireland brought in 49% and Ireland brought in under 1% of revenue in Q1 fiscal 2027.

The fastest-growing business segment from a year earlier was Cardiovascular (+19.5%).

From company filings, in USD; latest quarter ended July 31, 2026; quarterly data from Q2 fiscal 2018.

Medtronic plc

MDTHealthcare Ireland

Ireland

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

CardiovascularNeuroscience GroupMedical SurgicalCardiac and Vascular GroupDiabetes GroupMinimally Invasive Therapies GroupRestorative Therapies GroupOther Operating Segments, Including DiabetesOther

Q1 FY27 breakdown

Fiscal quarter ended Jul 31, 2026

Item	Revenue	Share	vs year before	Trend
Cardiovascular	USD 3.93B	40.3%	+19.5%
Neuroscience Group	USD 2.68B	27.4%	+10.3%
Medical Surgical	USD 2.28B	23.4%	+9.9%
Diabetes Group	USD 843.00M	8.6%	–
Other Operating Segment, Misc	USD 29.00M	0.3%	–	–

Sum of items USD 9.76B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18
Cardiovascular	3.9B	3.8B	3.5B	3.4B	3.3B	3.3B	3.0B	3.1B	3.0B	–	2.9B	2.9B	2.9B	–	2.8B	2.8B	2.7B	–	2.7B	2.8B	2.9B	–	2.7B	2.7B	2.4B	–	–	–	–	–	–	–	–	–	–	–
Neuroscience Group	2.7B	2.8B	2.6B	2.6B	2.4B	2.6B	2.5B	2.5B	2.3B	–	2.4B	2.3B	2.2B	–	2.2B	2.2B	2.1B	–	2.1B	2.1B	2.2B	–	2.1B	2.1B	1.7B	–	–	–	–	–	–	–	–	–	–	–
Medical Surgical	2.3B	2.4B	2.2B	2.2B	2.1B	2.2B	2.1B	2.1B	2.0B	–	2.1B	2.1B	2.0B	–	2.1B	2.0B	1.9B	–	2.3B	2.3B	2.3B	–	2.3B	2.3B	1.8B	–	–	–	–	–	–	–	–	–	–	–
Cardiac and Vascular Group	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.8B	2.9B	2.8B	–	2.8B	2.9B	2.8B	–	2.8B	2.8B
Diabetes Group	843.0M	838.0M	796.0M	757.0M	–	728.0M	694.0M	686.0M	647.0M	–	640.0M	610.0M	578.0M	–	570.0M	556.0M	541.0M	–	584.0M	585.0M	572.0M	–	630.0M	574.0M	562.0M	–	610.0M	596.0M	592.0M	–	610.0M	583.0M	572.0M	–	584.0M	462.0M
Minimally Invasive Therapies Group	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.2B	2.1B	2.1B	–	2.1B	2.0B	2.1B	–	2.0B	2.0B
Restorative Therapies Group	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.1B	2.1B	2.0B	–	2.0B	2.0B	1.9B	–	1.9B	1.9B
Other Operating Segments, Including Diabetes	–	–	–	–	755.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other	–	–	–	–	–	–	–	–	–	–	17.0M	22.0M	16.0M	–	81.0M	82.0M	81.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
All other segments	–	34.0M	32.0M	35.0M	34.0M	32.0M	32.0M	37.0M	38.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Operating Segment, Misc	29.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Medtronic revenue by business segment, last 4 quarters

Business segment	Q1 FY27	Q3 FY26	Q2 FY26	Q1 FY26	Share
Cardiovascular	$3.9B	$3.5B	$3.4B	$3.3B	40%
Neuroscience Group	$2.7B	$2.6B	$2.6B	$2.4B	27%
Medical Surgical	$2.3B	$2.2B	$2.2B	$2.1B	23%
Diabetes Group	$843.0M	$796.0M	$757.0M	–	9%
Other Operating Segment, Misc	$29.0M	–	–	–	under 1%

In USD, fiscal quarters as reported; share = part of Q1 FY27 revenue.

Medtronic revenue by region, last 4 quarters

Region	Q1 FY27	Q3 FY26	Q2 FY26	Q1 FY26	Share
United States	$4.9B	$4.5B	$4.5B	$4.2B	50%
Non-US	$4.9B	$4.5B	$4.4B	$4.4B	50%

In USD, fiscal quarters as reported; share = part of Q1 FY27 revenue.

Medtronic revenue by country, last 4 quarters

Country	Q1 FY27	Q3 FY26	Q2 FY26	Q1 FY26	Share
United States	$4.9B	$4.5B	$4.5B	$4.2B	50%
Total Other Countries, Excluding United States and Ireland	$4.8B	$4.5B	$4.4B	$4.3B	49%
Ireland	$40.0M	$36.0M	$35.0M	$33.0M	under 1%

In USD, fiscal quarters as reported; share = part of Q1 FY27 revenue.

Questions and answers

What are Medtronic's business segments?

Cardiovascular, Neuroscience Group, Medical Surgical, Diabetes Group and Other Operating Segment, Misc (as reported for Q1 fiscal 2027).

Which business segment makes the most money for Medtronic?

Cardiovascular: $3.93 billion, or 40% of revenue, in Q1 fiscal 2027.

Where does Medtronic make its money?

By region in Q1 fiscal 2027: United States (50%) and Non-US (50%).

MoreMedtronic stock overview Medtronic financials Medtronic executive team Medtronic shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

CardiovascularNeuroscience GroupMedical SurgicalCardiac and Vascular GroupDiabetes GroupMinimally Invasive Therapies GroupRestorative Therapies GroupOther Operating Segments, Including DiabetesOther

Q1 FY27 breakdown

Fiscal quarter ended Jul 31, 2026

Item	Revenue	Share	vs year before	Trend
Cardiovascular	USD 3.93B	40.3%	+19.5%
Neuroscience Group	USD 2.68B	27.4%	+10.3%
Medical Surgical	USD 2.28B	23.4%	+9.9%
Diabetes Group	USD 843.00M	8.6%	–
Other Operating Segment, Misc	USD 29.00M	0.3%	–	–

Sum of items USD 9.76B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18
Cardiovascular	3.9B	3.8B	3.5B	3.4B	3.3B	3.3B	3.0B	3.1B	3.0B	–	2.9B	2.9B	2.9B	–	2.8B	2.8B	2.7B	–	2.7B	2.8B	2.9B	–	2.7B	2.7B	2.4B	–	–	–	–	–	–	–	–	–	–	–
Neuroscience Group	2.7B	2.8B	2.6B	2.6B	2.4B	2.6B	2.5B	2.5B	2.3B	–	2.4B	2.3B	2.2B	–	2.2B	2.2B	2.1B	–	2.1B	2.1B	2.2B	–	2.1B	2.1B	1.7B	–	–	–	–	–	–	–	–	–	–	–
Medical Surgical	2.3B	2.4B	2.2B	2.2B	2.1B	2.2B	2.1B	2.1B	2.0B	–	2.1B	2.1B	2.0B	–	2.1B	2.0B	1.9B	–	2.3B	2.3B	2.3B	–	2.3B	2.3B	1.8B	–	–	–	–	–	–	–	–	–	–	–
Cardiac and Vascular Group	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.8B	2.9B	2.8B	–	2.8B	2.9B	2.8B	–	2.8B	2.8B
Diabetes Group	843.0M	838.0M	796.0M	757.0M	–	728.0M	694.0M	686.0M	647.0M	–	640.0M	610.0M	578.0M	–	570.0M	556.0M	541.0M	–	584.0M	585.0M	572.0M	–	630.0M	574.0M	562.0M	–	610.0M	596.0M	592.0M	–	610.0M	583.0M	572.0M	–	584.0M	462.0M
Minimally Invasive Therapies Group	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.2B	2.1B	2.1B	–	2.1B	2.0B	2.1B	–	2.0B	2.0B
Restorative Therapies Group	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.1B	2.1B	2.0B	–	2.0B	2.0B	1.9B	–	1.9B	1.9B
Other Operating Segments, Including Diabetes	–	–	–	–	755.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other	–	–	–	–	–	–	–	–	–	–	17.0M	22.0M	16.0M	–	81.0M	82.0M	81.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
All other segments	–	34.0M	32.0M	35.0M	34.0M	32.0M	32.0M	37.0M	38.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Operating Segment, Misc	29.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–